The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

Mon, 14th Jun 2021 20:33

(Alliance News) - The following is a round-up of updates by London-listed companies issued on Monday and not separately reported by Alliance News:

----------

TBC Bank Group PLC - Tbilisi, Georgia-headquartered lender - Says just under 24% of shareholders vote against approval of directors' remuneration report. "The executive remuneration arrangements reported on in the 2020 directors' remuneration report are fully aligned with our directors' remuneration policy, which was approved by 99.9% of our shareholders at our 2018 AGM," lender explains. It continues: "Over the last year, we have engaged with shareholders about executive remuneration in connection with the preparation of the new directors' remuneration policy, which the board notes was approved by 96.2% of shareholders at the AGM. We will continue our active dialogue with shareholders on executive remuneration matters, particularly with those who decided to vote against this resolution, and intend to further consult with shareholders during the coming months to understand their concerns." Also notes 25% of shareholders vote against resolution to disapply statutory pre-emption rights.

----------

Spectra Systems Corp - Rhode Island-based authentication technology provider - Reports lack of quorum at annual general meeting. Notes only 24% of shares voted, which came from 23 ballots.

----------

Cadence Minerals PLC - UK-based mineral resources investor - Says 1% investee Macarthur Minerals o spin-out its non-iron ore assets in the Pilbara into Infinity Mining Ltd. Infinity intends to IPO in Australia. "This strategy will fast track further exploration and the future development potential of the Pilbara Assets and allow Macarthur to focus solely on the development of its flagship iron ore projects situated at Lake Giles in the Yilgarn region of south-western, Western Australia," Macarthur explains.

----------

Braveheart Investment Group PLC - makes strategic investments in companies it thinks will outperform - Notes investee Paraytec's grant funded project to deploy its ActiPix technology in the field of Alzheimer's disease diagnosis is "progressing well". "Prototype instruments are being built, to test blood for protein biomarkers. If successful, these instruments will be used by clinicians aiming to more accurately diagnose patients and monitor their treatment," company adds.

----------

Yamana Gold Inc - gold, silver and copper miner in Canada, Chile, Brazil and Argentina - Agrees to buy the Francoeur, Arntfield and Lac Fortune gold properties adjoining the company's Wasamac project as well as additional claims in the Beuchastel township to the east of the Wasamac project from Globex Mining Enterprises Inc. Will pay CAD4.0 million, about USD3.3 million, in shares to Globex, with remaining CAD11.0 million, payable over 4 years, to be paid in either cash or shares. On top of that, Globex will receive a 2% gross metal royalty from Yamana, of which 0.5% may be bought back at any time by Yamana for CAD1.5 million, following which the royalty would be reduced to a 1.5% gross metal royalty.

----------

Secure Property Development & Investment PLC - eastern Europe focused property investor - Signs three agreements over transfer of certain assets owned by SPDI in Romania and Ukraine to Arcona Property Fund NV. Under the terms of the agreements, SPDI will receive approximately 605,000 new ordinary shares in Arcona and about 145,000 warrants over ordinary shares in Arcona, as well as EUR1 million in cash. Says transaction worth total of EUR8.2 million.

----------

Motif Bio PLC - AIM cash shell - Says BiVictriX Therapeutics Ltd acquisition cancelled after shareholders at annual general meeting vote against several resolutions. As a result, shares will be cancelled from trading on AIM on Tuesday. Has previously proposed name change to BiVictriX Therapeutics and placing and subscription to raise GBP10.1 million via issue of 50.5 million new shares, at a price of 20 pence each. Both of which will now not go ahead.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2020 11:16

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Read more
5 May 2020 10:58

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Read more
5 May 2020 09:17

Motif Bio raises ?0.65m as it hunts for reverse takeover opportunity

(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.

Read more
4 May 2020 15:42

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Read more
14 Apr 2020 17:12

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Read more
19 Mar 2020 14:51

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Read more
18 Mar 2020 15:33

Motif Bio struggling to find reverse takeover opportunity

(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.

Read more
28 Jan 2020 11:31

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Read more
26 Nov 2019 18:15

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Read more
18 Nov 2019 13:50

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Read more
11 Nov 2019 09:52

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Read more
11 Nov 2019 09:40

Motif Bio reaches settlement with former clinical research organisation

(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.

Read more
25 Oct 2019 17:34

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Read more
24 Oct 2019 16:05

Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.

Read more
24 Oct 2019 12:01

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.